PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · May 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called perampanel to prevent seizures in patients who have survived a cardiac arrest. Seizures can be a serious problem for these patients, with about one in three experiencing them after their heart stops and is restarted. The trial aims to see if perampanel is safe and effective for helping these patients avoid seizures after they have been resuscitated.

To be eligible for this study, participants must be at least 18 years old and have experienced a non-traumatic cardiac arrest outside of a hospital. They should be in a coma when admitted to the hospital and have had their heart restarted within 45 minutes of the arrest. Patients who have certain medical issues, such as severe liver or kidney problems, or those who are pregnant, cannot participate. If someone joins the trial, they will receive either the medication or a placebo (a dummy treatment) to see how well it works. The study is currently looking for participants at Zuckerberg San Francisco General Hospital.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old
• • Non-traumatic, out-of-hospital cardiac arrest
• • Comatose on admission - defined as not following commands
• • Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
• • Admission to the intensive care unit at Zuckerberg San Francisco General Hospital
• Exclusion Criteria:
• • Acute cerebral hemorrhage or infarction
• • Pregnancy
• • Prisoner
• • Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
• • Severe liver impairment with liver function tests five times above the upper limit of normal
• • Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest